Intelligent Pharmacy最新文献_第2页

Capitalization of digital healthcare: The cornerstone of emerging medical practices 数字化医疗的资本化：新兴医疗实践的基石

Intelligent Pharmacy

Pub Date : 2025-10-01 DOI: 10.1016/j.ipha.2024.12.002

Subhajit Hazra, Kundan Singh Bora

Background

The digital healthcare sector in India is rapidly transforming, driven by strategic government initiatives and technological advancements. In 2020, the market was valued at approximately $1.5 billion and is projected to grow at a compound annual growth rate of ∼25% over the next five years.

Methodology

The study employed a descriptive and analytical approach, reviewing existing literature and data on the applications and implications of AI, mHealth, and GIS technologies in healthcare.

Result

The article highlighted the rapid growth of India's digital health market, driven by the adoption of telemedicine, mobile health, and electronic health records, alongside increased investments and internet penetration. Additionally, it also raised concerns about bias, transparency, and accountability in these technologies, urging the development of robust digital infrastructure, including Digital Health IDs, Health Facility Registries, and Healthcare Professionals Registries, as well as policy changes like the effective implementation of Personal Data Protection Bill and updates to the Information Technology Act.

Conclusion

India's healthcare market is at a critical juncture, where effective management of the ongoing digital transformation can vastly improve access and outcomes for millions. By tackling current challenges and embracing technological advancements, India could set a global standard in digital healthcare, ensuring equitable, high-quality care for all citizens, regardless of location or socio-economic status. The vision of a fully integrated digital healthcare system is not just possible but an impending reality that, with the right strategies and collaborations, could be realized within the next decade.

在政府战略举措和技术进步的推动下，印度的数字医疗行业正在迅速转型。2020年，该市场价值约为15亿美元，预计未来五年将以25%的复合年增长率增长。本研究采用了描述性和分析性的方法，回顾了关于人工智能、移动医疗和地理信息系统技术在医疗保健中的应用和影响的现有文献和数据。这篇文章强调了印度数字医疗市场的快速增长，这主要得益于远程医疗、移动医疗和电子健康记录的采用，以及投资的增加和互联网的普及。此外，报告还提出了对这些技术中的偏见、透明度和问责制的担忧，敦促发展强大的数字基础设施，包括数字健康id、卫生设施注册和医疗保健专业人员注册，以及有效实施《个人数据保护法案》和更新《信息技术法案》等政策变化。印度的医疗保健市场正处于关键时刻，对正在进行的数字化转型进行有效管理可以极大地改善数百万人的就诊机会和结果。通过应对当前的挑战和拥抱技术进步，印度可以在数字医疗保健方面树立全球标准，确保所有公民，无论身处何地或社会经济地位如何，都能获得公平、高质量的医疗服务。一个完全集成的数字医疗保健系统的愿景不仅是可能的，而且是一个即将到来的现实，通过正确的战略和合作，可以在未来十年内实现。

{"title":"Capitalization of digital healthcare: The cornerstone of emerging medical practices","authors":"Subhajit Hazra, Kundan Singh Bora","doi":"10.1016/j.ipha.2024.12.002","DOIUrl":"10.1016/j.ipha.2024.12.002","url":null,"abstract":"<div><h3>Background</h3><div>The digital healthcare sector in India is rapidly transforming, driven by strategic government initiatives and technological advancements. In 2020, the market was valued at approximately $1.5 billion and is projected to grow at a compound annual growth rate of ∼25% over the next five years.</div></div><div><h3>Methodology</h3><div>The study employed a descriptive and analytical approach, reviewing existing literature and data on the applications and implications of AI, mHealth, and GIS technologies in healthcare.</div></div><div><h3>Result</h3><div>The article highlighted the rapid growth of India's digital health market, driven by the adoption of telemedicine, mobile health, and electronic health records, alongside increased investments and internet penetration. Additionally, it also raised concerns about bias, transparency, and accountability in these technologies, urging the development of robust digital infrastructure, including Digital Health IDs, Health Facility Registries, and Healthcare Professionals Registries, as well as policy changes like the effective implementation of Personal Data Protection Bill and updates to the Information Technology Act.</div></div><div><h3>Conclusion</h3><div>India's healthcare market is at a critical juncture, where effective management of the ongoing digital transformation can vastly improve access and outcomes for millions. By tackling current challenges and embracing technological advancements, India could set a global standard in digital healthcare, ensuring equitable, high-quality care for all citizens, regardless of location or socio-economic status. The vision of a fully integrated digital healthcare system is not just possible but an impending reality that, with the right strategies and collaborations, could be realized within the next decade.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 5","pages":"Pages 309-322"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145195981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracellular vesicles as carriers for protein and peptide therapeutics delivery: A review 细胞外囊泡作为蛋白质和肽治疗药物递送的载体：综述

Intelligent Pharmacy

Pub Date : 2025-10-01 DOI: 10.1016/j.ipha.2025.05.001

Yohannes Mengesha, Mesay Wondaya, Mulualem Workye, Lielet Belete

Protein and peptide-based therapeutics hold immense potential for treating various diseases, including cancer, neurodegenerative disorders, and metabolic conditions. However, rapid degradation, poor bioavailability, short half-life, and early clearance limit their clinical application. Several protein and peptide modifications and drug delivery systems (DDS) tested including enzyme inhibitors, chemical modification and conventional nanoparticles have limitations like immune Reponses, extracellular vesicles (EVs), present a good solution to overcome this drawbacks. EVs have gained attention as novel delivery systems for protein and peptide therapeutics owing to their small size, biocompatibility, intrinsic targeting capabilities, lower immunogenicity, and ability to protect cargo from enzymatic degradation. EVs have demonstrated promising results in preclinical studies by enhancing the uptake, loading, penetration, and targeted release of protein/peptide cargos for conditions such as cancer, diabetes, and microbial infections. Additionally, they can serve as carriers for targeting peptides, enabling the delivery of synthetic drugs and genome-editing tools. This review explores the potential of EVs as drug delivery systems (DDS) for protein and peptide drugs, focusing on their advantages and characteristics, engineering and encapsulation, emerging EV and EV-cargo characterization techniques, release, and efficacy in overcoming the limitations of protein- and peptide-based delivery systems. The review also addresses challenges and future perspectives in translating EV-based protein and peptide delivery systems into clinical practice.

基于蛋白质和多肽的治疗方法在治疗各种疾病，包括癌症、神经退行性疾病和代谢疾病方面具有巨大的潜力。然而，降解快，生物利用度差，半衰期短，早期清除限制了它们的临床应用。经过测试的几种蛋白质和肽修饰和药物传递系统（DDS），包括酶抑制剂、化学修饰和传统纳米颗粒，具有免疫反应等局限性，细胞外囊泡（ev）提供了克服这些缺点的良好解决方案。电动汽车由于其体积小、生物相容性好、内在靶向能力强、免疫原性低以及保护货物免受酶降解的能力，作为蛋白质和肽治疗的新型递送系统而受到关注。在临床前研究中，电动汽车通过增强蛋白质/肽货物的摄取、装载、渗透和靶向释放，为癌症、糖尿病和微生物感染等疾病提供了有希望的结果。此外，它们可以作为靶向肽的载体，实现合成药物和基因组编辑工具的递送。本文综述了电动汽车作为蛋白质和多肽药物递送系统（DDS）的潜力，重点介绍了它们的优势和特点、工程和封装、新兴的电动汽车和电动汽车货物表征技术、释放以及在克服蛋白质和肽基递送系统局限性方面的功效。该综述还讨论了将基于ev的蛋白质和肽递送系统转化为临床实践的挑战和未来前景。

{"title":"Extracellular vesicles as carriers for protein and peptide therapeutics delivery: A review","authors":"Yohannes Mengesha, Mesay Wondaya, Mulualem Workye, Lielet Belete","doi":"10.1016/j.ipha.2025.05.001","DOIUrl":"10.1016/j.ipha.2025.05.001","url":null,"abstract":"<div><div>Protein and peptide-based therapeutics hold immense potential for treating various diseases, including cancer, neurodegenerative disorders, and metabolic conditions. However, rapid degradation, poor bioavailability, short half-life, and early clearance limit their clinical application. Several protein and peptide modifications and drug delivery systems (DDS) tested including enzyme inhibitors, chemical modification and conventional nanoparticles have limitations like immune Reponses, extracellular vesicles (EVs), present a good solution to overcome this drawbacks. EVs have gained attention as novel delivery systems for protein and peptide therapeutics owing to their small size, biocompatibility, intrinsic targeting capabilities, lower immunogenicity, and ability to protect cargo from enzymatic degradation. EVs have demonstrated promising results in preclinical studies by enhancing the uptake, loading, penetration, and targeted release of protein/peptide cargos for conditions such as cancer, diabetes, and microbial infections. Additionally, they can serve as carriers for targeting peptides, enabling the delivery of synthetic drugs and genome-editing tools. This review explores the potential of EVs as drug delivery systems (DDS) for protein and peptide drugs, focusing on their advantages and characteristics, engineering and encapsulation, emerging EV and EV-cargo characterization techniques, release, and efficacy in overcoming the limitations of protein- and peptide-based delivery systems. The review also addresses challenges and future perspectives in translating EV-based protein and peptide delivery systems into clinical practice.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 5","pages":"Pages 350-367"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoliposome as a carrier for topical delivery of oxymetazoline hydrochloride: In-vitro assessment and in-vivo anti-inflammatory potential 纳米脂质体作为局部递送盐酸羟甲唑啉的载体：体外评估和体内抗炎潜能

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.09.006

Banhishikha Kar , Beduin Mahanti , Ayan Kumar Kar , Subhabrota Majumdar

The present investigation on nanoliposome infused with oxymetazoline hydrochloride was fabricated with phosphatidylcholine and cholesterol to effectively deliver the drug to the skin. Oxymetazoline hydrochloride evidence to show anti-inflammatory characteristics. The drug produces pro-resolving lipoxins in accordance with the formation of anti-inflammatory 15(S)-hydroxy-eicosatetraenoic acid and the consequent reduction of pro-inflammatory lipid mediators such as leukotriene B4 which leads to the reduction in inflammation at the topical region. The oxymetazoline hydrochloride infused nanoliposomes were prepared by thin film lipid hydration method. The present research assessed the average particle size of different formulations ranges from 147.4 ± 0.77 nm to 371.7 ± 0.99 nm with polydispersity value ranging from 0.181 ± 0.02 to 0.392 ± 0.03. Furthermore, the zeta potentials ranging from −15.2 ± 0.25 mV to −30.5 ± 0.24 mV. The percentage of drug release at 12 h (Y1) has a p-value of 0.0073, entrapment efficiency (%) (Y2) has p-value of 0.0001 and particle size (nm) (Y3) has a p-value of 0.0480. Hence all the dependent responses found to be significant. This study exhibited small particle size distribution with consistent polydispersity index which ensure the monodispersed nature of the nanoliposomes. The satisfactory zeta potential value indicates the stability of formulation. The outcome of the study projected that oxymetazoline hydrochloride loaded nanoliposome have the potential to deliver drugs to specific regions with their high stability and predictable release at the target region.

本研究以磷脂酰胆碱和胆固醇为主要成分，制备了注入盐酸羟甲唑啉的纳米脂质体，使药物有效地传递到皮肤。盐酸羟美唑啉有抗炎作用。该药物根据抗炎15(S)-羟基二十碳四烯酸的形成产生促溶解脂毒素，并随之减少促炎脂质介质，如白三烯B4，从而减少局部区域的炎症。采用薄膜脂质水合法制备了注入盐酸羟甲唑啉的纳米脂质体。不同配方的平均粒径范围为147.4±0.77 nm ~ 371.7±0.99 nm，多分散度值为0.181±0.02 ~ 0.392±0.03。zeta电位范围为- 15.2±0.25 mV至- 30.5±0.24 mV。12 h药物释放率（Y1）的p值为0.0073，包封效率（%）（Y2）的p值为0.0001，粒径（nm）（Y3）的p值为0.0480。因此，所有的依赖反应都是显著的。本研究显示了具有一致的多分散性指数的小粒径分布，这确保了纳米脂质体的单分散性。zeta电位值令人满意，表明制剂的稳定性。研究结果表明，负载盐酸羟甲唑啉纳米脂质体具有高稳定性和可预测的靶区释放，具有将药物输送到特定区域的潜力。

{"title":"Nanoliposome as a carrier for topical delivery of oxymetazoline hydrochloride: In-vitro assessment and in-vivo anti-inflammatory potential","authors":"Banhishikha Kar , Beduin Mahanti , Ayan Kumar Kar , Subhabrota Majumdar","doi":"10.1016/j.ipha.2024.09.006","DOIUrl":"10.1016/j.ipha.2024.09.006","url":null,"abstract":"<div><div>The present investigation on nanoliposome infused with oxymetazoline hydrochloride was fabricated with phosphatidylcholine and cholesterol to effectively deliver the drug to the skin. Oxymetazoline hydrochloride evidence to show anti-inflammatory characteristics. The drug produces pro-resolving lipoxins in accordance with the formation of anti-inflammatory 15(S)-hydroxy-eicosatetraenoic acid and the consequent reduction of pro-inflammatory lipid mediators such as leukotriene B4 which leads to the reduction in inflammation at the topical region. The oxymetazoline hydrochloride infused nanoliposomes were prepared by thin film lipid hydration method. The present research assessed the average particle size of different formulations ranges from 147.4 ± 0.77 nm to 371.7 ± 0.99 nm with polydispersity value ranging from 0.181 ± 0.02 to 0.392 ± 0.03. Furthermore, the zeta potentials ranging from −15.2 ± 0.25 mV to −30.5 ± 0.24 mV. The percentage of drug release at 12 h (Y1) has a <em>p</em>-value of 0.0073, entrapment efficiency (%) (Y2) has <em>p</em>-value of 0.0001 and particle size (nm) (Y3) has a <em>p</em>-value of 0.0480. Hence all the dependent responses found to be significant. This study exhibited small particle size distribution with consistent polydispersity index which ensure the monodispersed nature of the nanoliposomes. The satisfactory zeta potential value indicates the stability of formulation. The outcome of the study projected that oxymetazoline hydrochloride loaded nanoliposome have the potential to deliver drugs to specific regions with their high stability and predictable release at the target region.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 4","pages":"Pages 256-267"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alkaloids unveiled: A comprehensive analysis of novel therapeutic properties, mechanisms, and plant-based innovations 生物碱揭牌：对新的治疗特性、机制和基于植物的创新进行全面分析

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.09.007

Sarvananda Letchuman , H.D.T. Madhuranga , B.L.N.K. Madhurangi , Amal D. Premarathna , Muthupandian Saravanan

Alkaloids, naturally occurring compounds in a diverse range of plant species (Coffea spp., Erythroxylum coca, Cinchona spp. etc.), hold vast potential for biological, medicinal, and pharmacological applications. As the global focus shifts towards natural therapeutic agents due to their lower toxicity compared to synthetic compounds, this review takes a novel approach by examining the ecological and molecular factors influencing the medicinal properties of alkaloids. Using a comparative analysis of alkaloid potency across various plant species, we explore how environmental factors, such as soil composition and climate, impact alkaloid concentration and efficacy. Additionally, this review highlights the synergistic potential of alkaloids when combined with other phytochemicals, offering new insights into more potent, multi-compound therapeutic formulations. We documented ten key medicinal properties, including antioxidant, anti-inflammatory, and anticancer effects, and delve into the molecular pathways through which alkaloids exert these benefits. By exploring alkaloids from under-researched plant species, we aim to broaden the scope of medicinal applications, particularly within the realm of personalized medicine, where alkaloid efficacy may vary based on genetic and pathological factors. This novel perspective emphasized the need for further research to optimize alkaloid extraction methods and assess their potential in personalized and combination therapies, ultimately paving the way for more effective natural treatments.

生物碱是多种植物（咖啡、古柯红、金鸡纳等）中天然存在的化合物，在生物学、医学和药理学方面具有巨大的应用潜力。由于天然生物碱具有较低的毒性，因此全球关注的焦点转向天然治疗药物，本文从生态学和分子生物学的角度探讨了影响生物碱药性的因素。通过对不同植物种类生物碱效价的比较分析，探讨了土壤成分和气候等环境因素对生物碱浓度和效价的影响。此外，这篇综述强调了生物碱与其他植物化学物质结合时的协同作用潜力，为更有效的多化合物治疗配方提供了新的见解。我们记录了10个关键的药用特性，包括抗氧化、抗炎和抗癌作用，并深入研究了生物碱发挥这些功效的分子途径。通过从未充分研究的植物物种中探索生物碱，我们的目标是扩大医学应用的范围，特别是在个性化医疗领域，生物碱的功效可能根据遗传和病理因素而变化。这一新观点强调需要进一步研究优化生物碱提取方法，并评估其在个性化和联合治疗中的潜力，最终为更有效的自然治疗铺平道路。

{"title":"Alkaloids unveiled: A comprehensive analysis of novel therapeutic properties, mechanisms, and plant-based innovations","authors":"Sarvananda Letchuman , H.D.T. Madhuranga , B.L.N.K. Madhurangi , Amal D. Premarathna , Muthupandian Saravanan","doi":"10.1016/j.ipha.2024.09.007","DOIUrl":"10.1016/j.ipha.2024.09.007","url":null,"abstract":"<div><div>Alkaloids, naturally occurring compounds in a diverse range of plant species (<em>Coffea</em> spp., <em>Erythroxylum coca</em>, <em>Cinchona</em> spp. etc.), hold vast potential for biological, medicinal, and pharmacological applications. As the global focus shifts towards natural therapeutic agents due to their lower toxicity compared to synthetic compounds, this review takes a novel approach by examining the ecological and molecular factors influencing the medicinal properties of alkaloids. Using a comparative analysis of alkaloid potency across various plant species, we explore how environmental factors, such as soil composition and climate, impact alkaloid concentration and efficacy. Additionally, this review highlights the synergistic potential of alkaloids when combined with other phytochemicals, offering new insights into more potent, multi-compound therapeutic formulations. We documented ten key medicinal properties, including antioxidant, anti-inflammatory, and anticancer effects, and delve into the molecular pathways through which alkaloids exert these benefits. By exploring alkaloids from under-researched plant species, we aim to broaden the scope of medicinal applications, particularly within the realm of personalized medicine, where alkaloid efficacy may vary based on genetic and pathological factors. This novel perspective emphasized the need for further research to optimize alkaloid extraction methods and assess their potential in personalized and combination therapies, ultimately paving the way for more effective natural treatments.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 4","pages":"Pages 268-276"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design representation of pain visualization coding 疼痛可视化编码的设计表示

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.11.001

Yirui Wang , Xiaoling Wu , Li Tang , Yingjie Fei , Hengyu Guo , Yujun Wang , Wei Zhao , Siqian Zheng , Bowen Sun , Xia Wang

This paper proposes an innovative method for visualizing pain by transforming complex pain metrics into intuitive visual codes, making pain expression more precise and easier to understand and empathize with. The system categorizes pain by type, source, intensity, and range, employing creative visual elements to vividly represent these categories. This design not only enhances the clarity and accuracy of pain communication but also bridges the gap between patient experience and medical interpretation, providing a more human-centered solution in the healthcare field.

本文提出了一种创新的疼痛可视化方法，将复杂的疼痛度量转换为直观的视觉代码，使疼痛表达更精确，更容易理解和同情。该系统将疼痛按类型、来源、强度和范围进行分类，并采用创造性的视觉元素生动地表现这些类别。该设计不仅提高了疼痛沟通的清晰度和准确性，而且弥合了患者体验和医疗解释之间的差距，为医疗保健领域提供了更加以人为本的解决方案。

引用次数: 0

Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications 纳米结构脂质载体作为药物传递系统：与治疗应用的综合综述

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.09.005

Jyotiraditya Mall, Nazish Naseem, Md Faheem Haider, Md Azizur Rahman, Sara Khan, Sana Naaz Siddiqui

Recent advances in nanotechnology have enabled significant developments in health through innovative drug delivery systems. Nanostructured lipid carriers (NLCs) have emerged as a key technology in this field, offering enhanced drug stability, improved loading capacity, and reduced drug leakage compared to traditional solid lipid nanoparticles (SLNs). NLCs, such as ARM-NLC and PIO-loaded NLCs are specifically designed to optimize drug delivery and efficacy. Unlike other nanocarriers, NLCs provide controlled release and targeted delivery, making them highly effective for treating a range of diseases. Their applications include the treatment of skin cancer, Parkinson's disease, Alzheimer's disease, and breast cancer. The use of surface-engineered nanolayer coatings in NLCs has demonstrated significant improvements in targeting and delivering medications and bioactive substances to infection sites. Both in vitro and in vivo studies have shown promising results regarding the safety and efficacy of these NLC-based drug delivery systems.

纳米技术的最新进展通过创新的给药系统使卫生领域取得了重大发展。纳米结构脂质载体（nlc）已成为该领域的关键技术，与传统的固体脂质纳米颗粒（sln）相比，它具有更高的药物稳定性、更高的负载能力和更少的药物泄漏。nlc，如ARM-NLC和pio负载nlc是专门设计用于优化药物传递和疗效的。与其他纳米载体不同，NLCs提供可控释放和靶向递送，使其对治疗一系列疾病非常有效。它们的应用包括皮肤癌、帕金森病、阿尔茨海默病和乳腺癌的治疗。在nclc中使用表面工程纳米涂层已经证明了在靶向和向感染部位递送药物和生物活性物质方面的显著改进。体外和体内研究都显示了这些基于nlc的给药系统的安全性和有效性。

{"title":"Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications","authors":"Jyotiraditya Mall, Nazish Naseem, Md Faheem Haider, Md Azizur Rahman, Sara Khan, Sana Naaz Siddiqui","doi":"10.1016/j.ipha.2024.09.005","DOIUrl":"10.1016/j.ipha.2024.09.005","url":null,"abstract":"<div><div>Recent advances in nanotechnology have enabled significant developments in health through innovative drug delivery systems. Nanostructured lipid carriers (NLCs) have emerged as a key technology in this field, offering enhanced drug stability, improved loading capacity, and reduced drug leakage compared to traditional solid lipid nanoparticles (SLNs). NLCs, such as ARM-NLC and PIO-loaded NLCs are specifically designed to optimize drug delivery and efficacy. Unlike other nanocarriers, NLCs provide controlled release and targeted delivery, making them highly effective for treating a range of diseases. Their applications include the treatment of skin cancer, Parkinson's disease, Alzheimer's disease, and breast cancer. The use of surface-engineered nanolayer coatings in NLCs has demonstrated significant improvements in targeting and delivering medications and bioactive substances to infection sites. Both <em>in vitro</em> and <em>in vivo</em> studies have shown promising results regarding the safety and efficacy of these NLC-based drug delivery systems.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 4","pages":"Pages 243-255"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in transdermal drug delivery systems: Enhancing medicine with pain-free and controlled drug release 经皮给药系统的进展：以无痛和药物释放控制增强药物

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.09.008

E. Karthikeyan , S. Sivaneswari

Transdermal Drug Delivery Systems (TDDSs) provide controlled and prolonged drug release, enhance patient compliance, reduce gastrointestinal side effects, and improve drug stability. By delivering medication directly through the skin, TDDSs avoid the initial breakdown of the drug in the liver, which can enhance the amount of medication that reaches the bloodstream. The noninvasive nature of TDDSs reduces discomfort for patients by eliminating the need for invasive procedures like injections, enabling uninterrupted use throughout the day. Innovations such as the development of microneedles with adjustable depths and nanoparticles with targeted drug delivery capabilities have significantly improved the accuracy and efficiency of TDDSs. TDDSs have potential applications beyond pain management, including treating chronic conditions such as diabetes and hypertension.

经皮给药系统（TDDSs）提供控制和延长药物释放，增强患者依从性，减少胃肠道副作用，提高药物稳定性。通过直接通过皮肤给药，TDDSs避免了药物在肝脏的初始分解，这可以增加到达血液的药物量。TDDSs的非侵入性消除了注射等侵入性手术的需要，从而减少了患者的不适，使其全天不间断使用。诸如可调节深度的微针和具有靶向给药能力的纳米颗粒的开发等创新大大提高了TDDSs的准确性和效率。TDDSs在疼痛管理之外还有潜在的应用，包括治疗慢性疾病，如糖尿病和高血压。

引用次数: 0

Ensuring data integrity: Best practices and strategies in pharmaceutical industry 确保数据完整性：制药行业的最佳实践和策略

Intelligent Pharmacy

Pub Date : 2025-08-01 DOI: 10.1016/j.ipha.2024.09.010

Divya Gokulakrishnan, Sowmyalakshmi Venkataraman

Background

The objective of this article is to examine the challenges and best strategies for incorporating data integrity in the pharmaceutical industry to ensure regulatory compliance. It highlights the importance of data governance policies, secure data handling processes, and the use of the ALCOA framework for implementing Good Documentation Practices.

Evidence acquisition

Using appropriate search terms such as 'Data Integrity', 'Data Integrity in Pharmaceutical Industry', and 'ALCOA principle', evidence was gathered from websites and published articles using SciFinder, Web of Science, PubMed, UGC-approved journals, and Google Scholar databases.

Results

The article emphasizes the importance of change management, independent data review methods, and modern technology such as electronic signatures and audit trails in pharmaceutical companies. It also points out the importance of data backup, recovery procedures, and ongoing improvement in maintaining data integrity and promoting responsibility.

Conclusion

The article discusses the pharmaceutical sector's procedures for ensuring data integrity throughout a product's life, promoting safe, efficient, and excellent pharmaceutical goods. It highlights the need to navigate the complex regulatory environment and emphasizes the sector's commitment to maintaining data integrity to achieve high quality standards in manufacturing and testing operations.

本文的目的是研究在制药行业中整合数据完整性以确保法规遵从性的挑战和最佳策略。它强调了数据治理策略、安全数据处理流程以及使用ALCOA框架来实现良好文档实践的重要性。证据获取使用适当的搜索词，如“数据完整性”、“制药行业数据完整性”和“ALCOA原则”，从网站和发表的文章中收集证据，这些文章使用SciFinder、Web of Science、PubMed、ugc认可的期刊和谷歌Scholar数据库。结果本文强调了变革管理、独立数据审核方法以及电子签名和审计跟踪等现代技术在制药公司中的重要性。它还指出了数据备份、恢复程序以及在维护数据完整性和促进责任方面不断改进的重要性。本文讨论了制药部门在整个产品生命周期中确保数据完整性的程序，以促进安全，高效和优质的药品。它强调了在复杂的监管环境中导航的必要性，并强调了该行业致力于维护数据完整性，以实现制造和测试操作的高质量标准。

{"title":"Ensuring data integrity: Best practices and strategies in pharmaceutical industry","authors":"Divya Gokulakrishnan, Sowmyalakshmi Venkataraman","doi":"10.1016/j.ipha.2024.09.010","DOIUrl":"10.1016/j.ipha.2024.09.010","url":null,"abstract":"<div><h3>Background</h3><div>The objective of this article is to examine the challenges and best strategies for incorporating data integrity in the pharmaceutical industry to ensure regulatory compliance. It highlights the importance of data governance policies, secure data handling processes, and the use of the ALCOA framework for implementing Good Documentation Practices.</div></div><div><h3>Evidence acquisition</h3><div>Using appropriate search terms such as 'Data Integrity', 'Data Integrity in Pharmaceutical Industry', and 'ALCOA principle', evidence was gathered from websites and published articles using SciFinder, Web of Science, PubMed, UGC-approved journals, and Google Scholar databases.</div></div><div><h3>Results</h3><div>The article emphasizes the importance of change management, independent data review methods, and modern technology such as electronic signatures and audit trails in pharmaceutical companies. It also points out the importance of data backup, recovery procedures, and ongoing improvement in maintaining data integrity and promoting responsibility.</div></div><div><h3>Conclusion</h3><div>The article discusses the pharmaceutical sector's procedures for ensuring data integrity throughout a product's life, promoting safe, efficient, and excellent pharmaceutical goods. It highlights the need to navigate the complex regulatory environment and emphasizes the sector's commitment to maintaining data integrity to achieve high quality standards in manufacturing and testing operations.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 4","pages":"Pages 296-303"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the power of artificial intelligence in pharmaceuticals: Current trends and future prospects 在制药中利用人工智能的力量：当前趋势和未来前景

Intelligent Pharmacy

Pub Date : 2025-06-01 DOI: 10.1016/j.ipha.2024.12.001

Saha Aritra , Chauhan Baghel Shikha , Singh Indu

Introduction of artificial intelligence (AI) technology in the field of pharmaceutical industry has been driven to discovery and development of drugs, also personalized medicine. In this article The review investigates systematic trends facing AI-powered transformation. AI has improved efficiency by reducing the drug development time, costs and success rates due to machine learning (ML), deep learning (DL) and natural language processing (NLP). The literature search was conducted systematically, using core scientific databases to source data-mining research studies on predictive modelling, virtual screening, and automation in AI applications. Findings here underscore the critical role that AI plays in precision medicine, as well as process optimization in manufacture, but ethical issues and privacy of data and regulations add significantly to hurdles. The study confirms that AI presents unique opportunities for developing personalized healthcare and answering global health challenges, nonetheless its adoption involves overcoming ethical and regulatory issues beautiful collaboration and agreeing to industry wide standards. The next-generation products bring hope for low-cost, patient-centric solutions indicating pharmaceutical landscape phases of the paradigm.

人工智能（AI）技术在制药行业领域的引入，推动了药物的发现和开发，也推动了个性化医疗。在这篇文章中，综述调查了人工智能驱动转型面临的系统性趋势。由于机器学习（ML）、深度学习（DL）和自然语言处理（NLP），人工智能通过减少药物开发时间、成本和成功率来提高效率。系统地进行了文献检索，使用核心科学数据库来获取人工智能应用中预测建模、虚拟筛选和自动化方面的数据挖掘研究。研究结果强调了人工智能在精准医疗以及制造过程优化中发挥的关键作用，但道德问题、数据隐私和法规大大增加了障碍。该研究证实，人工智能为开发个性化医疗保健和应对全球健康挑战提供了独特的机会，尽管采用人工智能需要克服道德和监管问题，需要进行良好的合作，并符合行业标准。下一代产品为低成本，以患者为中心的解决方案带来了希望，这表明了范式的制药景观阶段。

{"title":"Harnessing the power of artificial intelligence in pharmaceuticals: Current trends and future prospects","authors":"Saha Aritra , Chauhan Baghel Shikha , Singh Indu","doi":"10.1016/j.ipha.2024.12.001","DOIUrl":"10.1016/j.ipha.2024.12.001","url":null,"abstract":"<div><div>Introduction of artificial intelligence (AI) technology in the field of pharmaceutical industry has been driven to discovery and development of drugs, also personalized medicine. In this article The review investigates systematic trends facing AI-powered transformation. AI has improved efficiency by reducing the drug development time, costs and success rates due to machine learning (ML), deep learning (DL) and natural language processing (NLP). The literature search was conducted systematically, using core scientific databases to source data-mining research studies on predictive modelling, virtual screening, and automation in AI applications. Findings here underscore the critical role that AI plays in precision medicine, as well as process optimization in manufacture, but ethical issues and privacy of data and regulations add significantly to hurdles. The study confirms that AI presents unique opportunities for developing personalized healthcare and answering global health challenges, nonetheless its adoption involves overcoming ethical and regulatory issues beautiful collaboration and agreeing to industry wide standards. The next-generation products bring hope for low-cost, patient-centric solutions indicating pharmaceutical landscape phases of the paradigm.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 3","pages":"Pages 181-192"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and evaluation of empagliflozin-loaded solid lipid nanoparticles: Pharmacokinetics and pharmacodynamics for oral delivery 恩格列净负载固体脂质纳米颗粒的开发和评价：口服给药的药代动力学和药效学

Intelligent Pharmacy

Pub Date : 2025-06-01 DOI: 10.1016/j.ipha.2024.12.004

Ananda Kumar Chettupalli , Aziz Unnisa , Himabindu Peddapalli , Rajendra Kumar Jadi , Kachupally Anusha , Padmanabha Rao Amarachinta

Type 2 diabetes mellitus is frequently treated with empagliflozin (EZN), a sodium-glucose cotransporter 2 inhibitor. Solid lipid nanoparticles (SLNs) shield the drug from gastrointestinal breakdown and improve the bioavailability of lipophilic drugs. The aim of the study is to use SLNs to enhance EZN's pharmacokinetics and pharmacodynamics in the treatment of diabetes mellitus. To prepare EZN-loaded SLNs, central composite design (CCD) was employed. The optimized batch (optimized EZN-loaded SLNs) had the desired values of dependent variables Vesicle size (R1), Entrapment Efficiency (R2), and Cumulative Drug Release (CDR) (R3). This was achieved by using analysis of variance (ANOVA) to analyse independent variables such as lipid concentration (X1), surfactant concentration (X2), sonication time (X3), and homogenization speed (X4). F8 exhibited the highest drug entrapment (90.6% ± 2.8%), CDR (89.2 ± 3.6), and average particle size (98.6 ± 2.1 nm) among the 30 distinct formulated formulae (F1–F30). Based on the F-value and p-value, the model was determined to be significant for particle size, entrapment efficiency, and CDR. The actual values of particle size entrapment efficiency and CDR closely matched the projected values of the optimized batch. The in vitro release trials produced a burst release followed by a continuous release. When compared to the EZN solution, the relative bioavailability of EZN-loaded SLNs was 1.2 times higher, indicating superior protection against the gastrointestinal environment. In rats with streptozotocin-induced diabetes mellitus, the optimized EZN-loaded SLNs outperformed the basic drug suspension in terms of antidiabetic efficacy. One promising method for administering EZN in the treatment of diabetes mellitus is by SLNs.

2型糖尿病经常使用恩格列净（EZN）治疗，这是一种钠-葡萄糖共转运蛋白2抑制剂。固体脂质纳米颗粒（sln）保护药物免受胃肠道分解，提高亲脂性药物的生物利用度。研究目的是利用sln增强EZN治疗糖尿病的药代动力学和药效学。采用中心复合设计（CCD）制备ezn负载sln。优化后的批（优化的ezn负载sln）具有所需的因变量：囊泡大小（R1）、包封效率（R2）和累积药物释放（CDR）（R3）。这是通过方差分析（ANOVA）来分析诸如脂质浓度（X1）、表面活性剂浓度（X2）、超声时间（X3）和均质速度（X4）等自变量来实现的。F8的药物包封率（90.6%±2.8%）、CDR（89.2±3.6）、平均粒径（98.6±2.1 nm）在30个不同配方（F1-F30）中最高。根据f值和p值，确定该模型对粒径、捕获效率和CDR具有显著性。粒径截留效率和CDR的实际值与优化批次的预测值基本吻合。体外释放试验产生一阵释放，随后是连续释放。与EZN溶液相比，负载EZN的sln的相对生物利用度高1.2倍，表明其对胃肠道环境具有更好的保护作用。在链脲佐菌素诱导的糖尿病大鼠中，优化后的ezn负载sln的降糖效果优于基本药物混悬液。一种很有前景的治疗糖尿病的方法是使用sln。

{"title":"Development and evaluation of empagliflozin-loaded solid lipid nanoparticles: Pharmacokinetics and pharmacodynamics for oral delivery","authors":"Ananda Kumar Chettupalli , Aziz Unnisa , Himabindu Peddapalli , Rajendra Kumar Jadi , Kachupally Anusha , Padmanabha Rao Amarachinta","doi":"10.1016/j.ipha.2024.12.004","DOIUrl":"10.1016/j.ipha.2024.12.004","url":null,"abstract":"<div><div>Type 2 diabetes mellitus is frequently treated with empagliflozin (EZN), a sodium-glucose cotransporter 2 inhibitor. Solid lipid nanoparticles (SLNs) shield the drug from gastrointestinal breakdown and improve the bioavailability of lipophilic drugs. The aim of the study is to use SLNs to enhance EZN's pharmacokinetics and pharmacodynamics in the treatment of diabetes mellitus. To prepare EZN-loaded SLNs, central composite design (CCD) was employed. The optimized batch (optimized EZN-loaded SLNs) had the desired values of dependent variables Vesicle size (R1), Entrapment Efficiency (R2), and Cumulative Drug Release (CDR) (R3). This was achieved by using analysis of variance (ANOVA) to analyse independent variables such as lipid concentration (X1), surfactant concentration (X2), sonication time (X3), and homogenization speed (X4). F8 exhibited the highest drug entrapment (90.6% ± 2.8%), CDR (89.2 ± 3.6), and average particle size (98.6 ± 2.1 nm) among the 30 distinct formulated formulae (F1–F30). Based on the F-value and <em>p</em>-value, the model was determined to be significant for particle size, entrapment efficiency, and CDR. The actual values of particle size entrapment efficiency and CDR closely matched the projected values of the optimized batch. The in vitro release trials produced a burst release followed by a continuous release. When compared to the EZN solution, the relative bioavailability of EZN-loaded SLNs was 1.2 times higher, indicating superior protection against the gastrointestinal environment. In rats with streptozotocin-induced diabetes mellitus, the optimized EZN-loaded SLNs outperformed the basic drug suspension in terms of antidiabetic efficacy. One promising method for administering EZN in the treatment of diabetes mellitus is by SLNs.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 3","pages":"Pages 193-206"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144272264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0